Zurich-Schlieren, Switzerland, 2 November 2023
We are pleased to announce that TOPADUR PHARMA AG has been awarded an Innosuisse grant to fund our collaborative project with partners from Yonsei University and Juvic Inc. in South Korea. The project aims to develop new technologies for the treatment of systemic sclerosis. We thank Innosuisse and the Korea Institute for Advancement of Technology (KIAT) for their support.
TOPADUR in collaboration with the University Hospital of Zurich and the University of Zurich was awarded CHF 859k by Innosuisse.
Read moreDiabetic Retinopathy is a severe complication of diabetes and a cause of blindness in adults.
Read moreThe Switzerland Global Enterprise interviewed Reto Naef, CEO of TOPADUR PHARMA AG.
Read more